Present status of antiaggregating agents in coronary and cerebrovascular disease prevention.
D000818:Animals; D000925:Anticoagulants / Q000008:administration & dosage / Q000627:therapeutic use*; D001241:Aspirin / Q000008:administration & dosage / Q000627:therapeutic use; D002561:Cerebrovascular Disorders / Q000188:drug therapy / Q000517:prevention & control*; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000188:drug therapy / Q000517:prevention & control*; D004176:Dipyridamole / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D006801:Humans; D066298:In Vitro Techniques; D008297:Male; D010919:Placebos; D010973:Platelet Adhesiveness / Q000187:drug effects; D010974:Platelet Aggregation / Q000187:drug effects*; D013442:Sulfinpyrazone / Q000008:administration & dosage / Q000627:therapeutic use; D013927:Thrombosis / Q000188:drug therapy / Q000517:prevention & control
D000925:Anticoagulants; D010919:Placebos; D004176:Dipyridamole; D001241:Aspirin; D013442:Sulfinpyrazone